

Metabolic modulators as a treatment of atrial fibrillation

Citation for published version (APA):

Opacic, D. (2019). *Metabolic modulators as a treatment of atrial fibrillation*. [Doctoral Thesis, Maastricht University]. ProefschriftMaken Maastricht. <https://doi.org/10.26481/dis.20190704do>

Document status and date:

Published: 01/01/2019

DOI:

[10.26481/dis.20190704do](https://doi.org/10.26481/dis.20190704do)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Propositions

Metabolic modulators as a treatment of atrial fibrillation

Dragan Opačić

1. Little is known about the role of myocyte metabolism and tissue perfusion in the pathogenesis of AF (this thesis, chapter 2).
2. Trimetazidine and ranolazine are recognized as anti-anginal drugs with metabolism-modulating properties, of which the mechanism of action is still poorly understood.
3. The electrophysiological effects of Ranolazine are preserved, but not enhanced, in AF-induced ‘electrically remodelled’ atria (this thesis, chapter 3).
4. Metabolic modulation can inhibit several hallmarks of AF-induced atrial structural remodelling and preserve atrial function.
5. The improved endothelium-dependent vasodilation of atrial resistance arteries in AF is similar to that of coronary resistance arteries as a result of exercise training. (this thesis, chapter 5 and Muller et al. *Circulation*. 1994;89:2308-14.)
6. There is still an unmet need for safer, more atrial-selective antiarrhythmic drugs.
7. I_{K1} blockade with the Pentamidine analogue PA-6 can restore sinus rhythm without inducing ventricular arrhythmias. (this thesis, chapter 4)
8. Elk nadeel heb z'n voordeel. (Every disadvantage has its advantage.) (Johan Cruyff)
9. Our virtues and our failings are inseparable, like force and matter. When they separate, man is no more. (Nikola Tesla)
10. One who has not kept the goats, cannot even imagine what misery and trouble is. (Živojin Mišić)